Takeda brings to market Idursulfase for hunter syndrome, Velaglucerase Alpha for gaucher disease and Agalsidase Alfa for fabry disease
Takeda, a biopharmaceutical company announced the launch of its Enzyme Replacement Therapy portfolio for lysosomal storage disorders (LSD) in India in line with its commitment to address the unmet needs of patients living with rare diseases in India. Under lysosomal storage disorders – India has been recording the prevalence of hunter syndrome, gaucher disease and fabry disease. To address these, Takeda brings to the market Idursulfase for hunter syndrome, Velaglucerase Alpha for gaucher disease and Agalsidase Alfa for fabry disease.
According to Vineet Singhal, Country Head, Takeda India, “At Takeda, we are committed to patient care by developing innovative new medicines and making existing medicines more readily available. Takeda is working towards shortening the time to diagnosis for rare diseases, with the aim to help healthcare practitioners support patients along the entire journey to enable them to better manage their care. Takeda in India has also been the pioneer in the management of Haemophilia which has transformed the lives of thousands of patients.”